Company Reports , Featured Investments , Spotlight

This new firm’s first products tackle a sensitive issue in a tried-and-tested way…

30 Sep 2021 | by: Mark Sheridan

LOVE Pharma – Mixing innovative ideas with proven science to lead the way in women’s wellbeing

LOVE PHARMA CSE:LUV

The most successful businesses are often those that solve a problem in a new and innovative way.

And that is exactly what LOVE Pharma is doing.

However, the particular problem it is solving with several of its innovative, science-backed products is one that isn’t talked about nearly as much as it should be.

You see, LOVE Pharma is helping to tackle the issue of female sexual dysfunction, or FSD for short.

It’s not perhaps an area you’ll have ever thought to invest in before.

But, the fact is, in helping to address this growing concern, LOVE Pharma presents smart investors with a very exciting proposition now that it has come to the public.

Indeed, there’s no doubt that FSD is a major issue, but it’s only now being fully recognized.

It’s hard to put precise figures on the problem, because of the many different forms FSD can take, but it’s estimated that between 30-50% of women suffer from it in the US alone.

So, where the market for treatments of male sexual dysfunction is already well established and worth an estimated $2 billion

The market for equivalent products addressed to women is now expected to grow three times larger.

In fact, a recent report predicted that the market for FSD treatments will soar in value by nearly $280 million between 2021 and 2025 alone.

That’s a compound annual growth rate of 35%.

LOVE Pharma looks to set to claim a huge chunk of the space thanks to the innovative and already-proven treatments it has been developing and taking to market.

Given the potential revenues on offer as awareness of FSD grows…

Smart investors who get in on the ground floor could be primed to generate excellent returns on their investments.

DOWNLOAD OUR SPECIAL REPORT to learn how LOVE Pharma is revolutionizing the wellness space

A natural and more effective alternative to what’s currently on the market

For many women, especially those who are premenopausal or menopausal, one of the most significant symptoms of FSD is vaginal dryness.

It’s a sensitive subject, but one that needs tackling. For women, the issue can not only make sexual intercourse uncomfortable, but it can be a source of general discomfort, too.

To tackle the problem, LOVE Pharma has developed a topical gel called Bloom that can be applied directly to the area of discomfort. It then increases blood flow to help with lubrication, increases sensitivity, and reduces pain.

Bloom uses two key ingredients: menthol and L-arginine, which work in tandem to stimulate the body and help it lubricate itself naturally.

This is key.

You see, many existing lubricants on the market use petrochemicals that can significantly contribute to bacterial infections.

Bloom overcomes that problem.

It’s worth noting, too, that as well as working in a much more natural way, LOVE Pharma’s gel is clinically proven to be effective.

A study found that 80% of women were able to lubricate naturally more quickly using Bloom, while 70% said the lubrication was of a higher quality.

Not only that, but the research found that over two-thirds of women who had used the gel enjoyed a better, more intense sexual experience.

In its current form, the product has already gone through FDA medical clearance and is now being readied to be brought to market.

However, LOVE Pharma is not resting on its laurels. Despite its excellent existing results, the company continues to innovate, and is already looking at releasing a version of the gel that adds CBD to the mix.

Scientific studies suggest that adding this element—which is derived from MJ—could help to enhance the effects of its product further.

It could open the door to swathes of new consumers engaging with the current boom for the therapeutic substance

But while a potential addition to LOVE Pharma’s range like this is critical to itslong-term prospects…

It is just one of many ways in which the business is looking to expand its reach.

A strategic approach to product development looks to establish long-term success

LOVE PHARMA CSE:LUV

LOVE Pharma is conscious of over-saturating the women’s wellness and sexual wellness markets by releasing too many products at the same time.

It’s the same sound logic that stops Coca-Cola from putting all its different brands and flavors in front of consumers at once. It would be overwhelming, and sales of each product could suffer as a result.

It’s far more effective to stagger launches, allowing the market to absorb each product individually.

And this is why LOVE Pharma has teed-up a number of products that could provide a series of very exciting value catalysts further down the line.

The first is another topical gel aimed at helping couples who struggle to conceive in a natural way.

Like FSD, unexplained infertility among healthy couples is an issue that is just not covered in the mainstream media.

But the fact is, 75% of unexplained infertility cases are thought to be a result of insufficient natural lubrication.

This product – called ToConceive – once again uses a combination of menthol and L-arginine to help increase natural lubrication and increase the production of a protein called ‘albumin’, which, in turn, increases the chances of conception.

Again, some lubricants on the market have been found to actually damage sperm and reduce the chances of conception. But LOVE Pharma’s natural solution avoids that problem.

It also provides hope for healthy couples of avoiding the need to resort to expensive IVF treatments, which can cost many thousands.

Already cleared by the FDA and multi-patented, it’s yet another product on LOVE Pharma’s roster that could soon become a huge revenue generator.

What’s more, alongside this, LOVE Pharma is also working on natural and patented supplements aimed specifically at enhancing desire and sexual performance in both women and men.

The company is not limiting its focus to sexual wellness, either.

Indeed, it has also released a sub-lingual strip containing menthol, L-arginine, and CBD that can be dissolved under the tongue– much like those many put on their tongue to freshen their breath.

Evidence suggests that the delivery method used by these strips—which have now entered the market—can support the rapid and highly effective uptake of their ingredients.

Critically, versions of these strips containing other MJ derivatives and even psychedelics will also enter the market further down the line, offering up exposure to even more booming sectors.

For example, the latter market is expected to be worth some US$6.9 billion by 2027 from just US$2.1 billion in 2019…

For a deep dive into how LOVE Pharma is revolutionizing the pharma space, READ OUR EXCLUSIVE REPORT

Ready and rearing to hit the market running

As it stands, the various products LOVE Pharma intends to bring to market are already proven and licensed.

As we write, it is just a case of branding them, preparing for launch, and then releasing them through the numerous distribution partners LOVE Pharma has been cultivating with the intention of signing imminently.

Significant revenues are expected to follow very quickly.

And when you consider the market caps of established companies operating in similar spaces often sits in the billions…

It’s clear there is significant upside for LOVE Pharma to enjoy.

Investors will be pleased to hear the company is well-funded already. So, with a winning team at the helm, there’s little doubt this is a stock set to lead the way in a number of interesting and important sectors.

It all adds up to an excellent addition that will help to diversify and potentially grow any portfolio.


IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by LOVE Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of two hundred and sixteen thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.

Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

  • Mark Sheridan does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.
  • Mark Sheridan has been paid to produce this piece by the company or companies mentioned above.
  • Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.
  • Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production this piece by the company or companies mentioned above.

More News & Analysis